Low Dose Naltrexone (LDN) in Australia: What the Evidence Shows for Fibromyalgia, Chronic Fatigue, and Chronic Pain
TL;DR
Low dose naltrexone (LDN) is an off-label medication prescribed at 1.5 to 4.5mg daily for conditions including fibromyalgia and ME/CFS. It works by reducing neuroinflammation rather than blocking pain signals. Multiple meta-analyses show promising but mixed results for fibromyalgia pain reduction. Australian and international clinical trials are currently investigating LDN for ME/CFS and long COVID. LDN is not TGA approved for these conditions. It is prescribed off-label by an AHPRA registered GP and dispensed by a compounding pharmacy. No treatment outcome guarantees apply.
Low dose naltrexone is one of the most talked about emerging therapies in chronic pain and fatigue medicine in Australia. For the estimated 2 to 5 percent of Australians living with fibromyalgia and the roughly 250,000 Australians affected by ME/CFS, standard treatments often provide only partial relief. Many patients spend years cycling through medications that address symptoms but not the underlying biology.
LDN takes a different approach. At doses far below those used for addiction medicine, naltrexone appears to reduce neuroinflammation: the chronic overactivation of immune cells in the brain and spinal cord that current research increasingly links to both fibromyalgia and ME/CFS. The evidence is growing, with multiple meta-analyses and active clinical trials published between 2024 and 2026. It is also incomplete, with small sample sizes and mixed results across studies.
This article explains what LDN is, how it works at a biological level, what the clinical trial data shows for fibromyalgia and chronic fatigue specifically, what the side effects are, and how to access LDN through a GP in Australia.
What Is Low Dose Naltrexone and How Does It Work?
Direct Answer
Low dose naltrexone (LDN) is naltrexone prescribed at 1.5 to 4.5mg daily, compared to the standard 50mg dose used for alcohol and opioid dependence. At this lower dose, LDN does not primarily block opioid receptors. It appears to reduce neuroinflammation by modulating microglial cells in the central nervous system and by antagonising Toll-like receptor 4 (TLR4), a key trigger of inflammatory cascades linked to chronic pain and fatigue conditions.
Naltrexone is a synthetic opioid receptor antagonist. The Therapeutic Goods Administration (TGA) approved it in Australia for the treatment of alcohol and opioid dependence at a dose of 50mg daily. At this standard dose, naltrexone blocks opioid receptors to reduce cravings and the rewarding effects of alcohol and opioids.
At much lower doses (typically 1.5 to 4.5mg), naltrexone appears to act through a completely different mechanism. Two pathways have been proposed and studied:
Microglial modulation via TLR4 antagonism. Microglia are the resident immune cells of the central nervous system. In conditions like fibromyalgia and ME/CFS, microglia appear to become chronically overactivated, releasing pro-inflammatory cytokines, nitric oxide, and substance P. This cascade drives central sensitisation: the nervous system becomes hypersensitive, amplifying pain signals and generating fatigue. LDN antagonises Toll-like receptor 4 (TLR4) on the surface of these glial cells, suppressing the inflammatory cascade. Dr. Jarred Younger at the University of Alabama described LDN as a “glial modulator” in a 2014 review published in Clinical Rheumatology.
Transient opioid receptor blockade and endorphin upregulation. A brief, partial blockade of opioid receptors at low doses may trigger a compensatory increase in endogenous opioid production (endorphins and enkephalins). This “rebound” effect could raise the body’s baseline pain threshold and improve mood and sleep regulation over time.
A third mechanism has been identified specifically in ME/CFS. Research led by Professor Sonya Marshall-Gradisnik at Griffith University’s National Centre for Neuroimmunology and Emerging Diseases (NCNED) on the Gold Coast found that ME/CFS patients show dysfunction in TRPM3 ion channels in natural killer (NK) cells. A 2021 study published in Frontiers in Immunology demonstrated that LDN restored TRPM3-like ionic currents in NK cells from ME/CFS patients. This provides a measurable biological marker of LDN’s effect, not just subjective symptom improvement.
These mechanisms make LDN biologically plausible for conditions driven by neuroinflammation and immune dysregulation, even though it is not a conventional painkiller.
Does LDN Help with Fibromyalgia? What the Clinical Trials Show
Direct Answer
Multiple systematic reviews and meta-analyses published between 2024 and 2025 show that LDN reduces pain scores in fibromyalgia patients compared to baseline. Some analyses also show superiority over placebo; others do not. The evidence is promising but not definitive. The largest individual trial (99 patients, Lancet Rheumatology, 2024) found LDN was not statistically superior to placebo for overall pain reduction, but a higher proportion of LDN patients achieved clinically meaningful pain relief (45% vs 28%). Larger, longer trials are underway.
The clinical evidence for LDN in fibromyalgia has grown substantially since the first pilot study in 2009. Here is what the key studies and reviews show:
Younger et al. 2009 (Pain Medicine): The first pilot study of LDN for fibromyalgia, conducted at Stanford University. Ten women with fibromyalgia received 4.5mg of naltrexone daily. The study reported reduced pain symptoms compared to placebo, prompting the larger follow-up trial.
Younger et al. 2013 (Arthritis & Rheumatism): A randomized, double-blind, placebo-controlled crossover trial with 31 women. Participants receiving LDN showed a mean pain reduction of 28.8% compared to 18.0% on placebo (P = 0.016). Thirty-two percent of participants achieved clinically meaningful response, defined as at least 30% reduction in pain plus 30% improvement in either fatigue or sleep. Dr. Younger noted this response rate was approximately double that of approved fibromyalgia medications.
Due Bruun et al. 2024, the FINAL Study (Lancet Rheumatology): The largest individual RCT to date, with 99 women randomized to naltrexone 6mg daily or placebo. The primary outcome (mean pain reduction) did not reach statistical significance (mean difference -0.34, P = 0.27). However, 45% of LDN patients achieved at least 30% pain reduction compared to 28% on placebo. The study also found that LDN may improve memory problems associated with fibromyalgia. An accompanying editorial asked whether LDN represents “another treatment disappointment” but noted the need for larger, longer trials before concluding.
2024 Meta-analysis, Korean Journal of Pain: A systematic review and meta-analysis of 4 RCTs involving 222 fibromyalgia patients with trial sequential analysis. Found a statistically significant reduction in pain scores favouring LDN (mean difference -0.86, 95% CI: -1.20 to -0.51, P < 0.001). Also reported increased pressure pain threshold in LDN groups, suggesting objective as well as subjective improvements.
Ologunowa et al. 2025 (Journal of Pain & Palliative Care Pharmacotherapy): A meta-analysis of 8 clinical studies (RCTs and clinical trials). Found that LDN reduced pain compared to baseline but did not show consistent superiority over placebo in head-to-head comparisons. The authors noted that included studies were small and heterogeneous, limiting the strength of conclusions.
Rizwan et al. 2025, ACR Convergence: An updated meta-analysis of 5 RCTs presented at the American College of Rheumatology annual meeting. Reported a pooled standardized mean difference of -0.851 (95% CI: -1.290 to -0.412) favouring LDN for pain reduction. Also reported a favourable safety profile with no serious adverse events attributed to LDN.
What does this mixed picture mean in practice? LDN is not a proven first-line treatment for fibromyalgia. The evidence base is growing but still consists of small trials with short follow-up periods. For patients who have already tried or cannot tolerate approved fibromyalgia medications (duloxetine, pregabalin, amitriptyline), LDN represents a low-cost, low-risk option with a plausible biological mechanism and encouraging (if not yet definitive) clinical data.
Can LDN Help with Chronic Fatigue Syndrome (ME/CFS)?
Direct Answer
Early evidence suggests LDN may reduce fatigue severity and improve immune cell function in ME/CFS patients. A retrospective study of 218 patients reported that 73.9% experienced a positive treatment response. Laboratory research at Griffith University in Australia demonstrated that LDN restores impaired ion channel function in immune cells from ME/CFS patients. However, large-scale randomized controlled trial data for ME/CFS specifically is not yet available. Multiple RCTs are currently underway in Australia, Canada, and the United States.
The evidence base for LDN in ME/CFS is at an earlier stage than for fibromyalgia, but several important findings and active trials are worth understanding:
Bolton et al. 2020 (Fatigue: Biomedicine, Health & Behavior): A retrospective analysis of 218 ME/CFS patients treated with LDN (3.0 to 4.5mg daily) over an average follow-up of 1.7 years. A positive treatment response was reported by 73.9% of patients. Most reported improved vigilance and alertness, along with better physical and cognitive performance. Some patients reported reduced pain and fever. Mild adverse effects (insomnia, nausea) were common early in treatment, but no severe or long-term adverse effects were reported.
Cabanas et al. 2021 (Frontiers in Immunology, Griffith University): This laboratory study used patch-clamp electrophysiology to examine natural killer (NK) cell function in ME/CFS patients taking LDN compared to healthy controls. The researchers found that LDN restored TRPM3-like ionic currents in NK cells from ME/CFS patients. This was the first in vitro confirmation that LDN may address a specific, measurable biological abnormality in ME/CFS, not just subjective symptoms.
Griffith University NCNED Clinical Trials (Australia): The National Centre for Neuroimmunology and Emerging Diseases at Griffith University launched a 12-week double-blind RCT of LDN (3 to 6mg daily) in ME/CFS patients in March 2026. This trial is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR Trial ID: 387311) and includes immunological, neurological, and brain MRI imaging endpoints. A separate Griffith trial is investigating LDN for long COVID patients.
Canadian RCT (UBC, Prof Luis Nacul): A double-blind, randomized trial of LDN for post-COVID fatigue syndrome, published as a protocol in BMJ Open (2024). Doses are titrated from 1mg to 4.5mg daily. As of September 2025, 208 participants had been pre-recruited, with 123 dosed and 76 having completed the full protocol. Results are expected in 2026.
Harvard LIFT Trial (Massachusetts General Hospital): The Life Improvement Trial is a randomized, placebo-controlled clinical trial investigating both LDN and pyridostigmine (Mestinon) for ME/CFS. The trial uses a four-arm design (LDN alone, pyridostigmine alone, both, or placebo) with a target of 160 participants. The protocol was published on Research Square in March 2025.
The pathway from LDN’s mechanism to fatigue relief is biologically coherent. Chronic microglial activation produces “sickness behaviour”: the profound fatigue, malaise, and cognitive slowing that the body generates in response to inflammation. In ME/CFS, this sickness behaviour appears to become self-sustaining. LDN’s proposed action, suppressing microglial activation and modulating TLR4 signalling, targets this process directly. It is not a stimulant and does not mask fatigue.
What Other Conditions Is LDN Being Studied For?
Beyond fibromyalgia and ME/CFS, LDN has been used or studied off-label in several other chronic conditions. This table summarizes the current landscape:
| Condition | Evidence Status | What Is Being Reported |
|---|---|---|
| Long COVID fatigue | Pilot studies, RCTs in progress | Reduced fatigue, improved quality of life scores, reduced brain fog in some studies |
| Crohn’s disease | Small blinded RCTs (Smith et al.) | Improved gastrointestinal symptoms and endoscopic remission rates |
| Multiple sclerosis | Small RCTs, observational data | Improved quality of life measures in some patients |
| Chronic widespread pain (nociplastic) | Off-label clinical use, case series | Reduced pain sensitivity and medication burden over time |
An integrative GP is best placed to assess which of these conditions is relevant to your situation and whether LDN is clinically appropriate.
What Are the Side Effects of Low Dose Naltrexone?
Direct Answer
LDN has a favourable safety profile at the doses used for chronic pain and fatigue (1.5 to 4.5mg daily). The most commonly reported side effects are vivid or unusual dreams and mild sleep disruption, particularly during the first 2 to 4 weeks. Some patients experience mild nausea early in treatment. These effects typically resolve as the body adjusts. No serious adverse events have been attributed to LDN in published clinical trials and meta-analyses. LDN does not cause dependency, sedation, or cognitive impairment at therapeutic doses.
Across the published RCTs and meta-analyses, the safety data is consistent:
- Vivid dreams: The most frequently reported side effect. The 2025 meta-analysis in Annals of Medicine & Surgery noted that LDN significantly increases the incidence of vivid dreams compared to placebo. This effect typically diminishes within the first few weeks of treatment.
- Mild nausea and headache: Reported by a minority of patients, usually in the first week and typically self-resolving.
- Sleep disturbance: Some patients notice mild insomnia or altered sleep patterns early in treatment. Taking LDN in the morning rather than at bedtime can help in these cases.
- No serious adverse events: No published trials have reported serious adverse events attributed to LDN at doses of 1.5 to 6mg daily.
Important contraindication: LDN must not be taken alongside opioid medications. Because naltrexone blocks opioid receptors (even at low doses), taking LDN with opioid pain medications would reduce or eliminate their effect and could trigger withdrawal symptoms. Patients must disclose all current medications to their GP before discussing LDN. A washout period is typically required before starting LDN if opioids have been used recently.
How Is LDN Prescribed and Accessed in Australia?
Direct Answer
LDN is prescribed off-label by an AHPRA-registered GP and dispensed by a compounding pharmacy. Standard naltrexone tablets are manufactured at 50mg, which is far too high for LDN therapy. Compounding pharmacies prepare LDN at the specified dose (typically 1.5 to 4.5mg capsules). LDN is not available on the Pharmaceutical Benefits Scheme (PBS). You do not need a specialist referral to discuss LDN with a GP.
In Australia, naltrexone is TGA approved at 50mg for the treatment of alcohol and opioid dependence. There is no TGA approved formulation at the low doses used for chronic pain and fatigue conditions. This means LDN is an off-label, compounded medication.
Off-label prescribing is a standard and legal part of Australian medical practice. It means the prescribing GP is using a medication outside its TGA approved indications, based on clinical evidence and their professional judgment that the treatment is appropriate for the individual patient.
The typical pathway to access LDN in Australia:
- Complete a pre-screening eligibility check to confirm that a telehealth consultation is appropriate for your situation. This takes approximately two minutes.
- Book an integrative health consultation with an AHPRA-registered GP. At Holistica Health, the initial integrative health consultation is $99 and is available to patients across all Australian states and territories via telehealth.
- Discuss your symptoms, medical history, and current medications with your GP. LDN will be considered alongside other integrative and conventional approaches based on your full clinical picture.
- If LDN is clinically appropriate, your GP will prescribe it at the starting dose and direct you to a suitable Australian compounding pharmacy. A follow-up consultation will be scheduled to review your response.
The standard dosing protocol starts at a low dose (usually 1.5mg daily) and is titrated gradually upward to the target range of 3 to 4.5mg over several weeks. This approach minimizes early side effects.
How Does LDN Compare to Standard Fibromyalgia and CFS Treatments?
| Treatment | Mechanism | TGA Status (Fibro/CFS) | Common Side Effects | Evidence Quality |
|---|---|---|---|---|
| Duloxetine (Cymbalta) | SNRI antidepressant | Approved (fibromyalgia) | Nausea, insomnia, sexual effects | Large RCTs |
| Pregabalin (Lyrica) | Anticonvulsant | Approved (fibromyalgia) | Drowsiness, weight gain, dizziness | Large RCTs |
| Amitriptyline | Tricyclic antidepressant | Off-label (fibro/CFS) | Sedation, dry mouth, weight gain | Moderate (older data) |
| Low Dose Naltrexone | Glial modulator, TLR4 antagonist | Off-label (compounded) | Vivid dreams, mild nausea (early) | Small RCTs, growing |
LDN does not replace these treatments. Many integrative GPs use LDN alongside existing medications (except opioids), adjusting based on patient response. The key distinction is the mechanism: LDN addresses central neuroinflammation rather than dampening pain signals or altering neurotransmitter levels.
What the Research Limitations Mean for Patients
An honest assessment of LDN’s evidence base requires acknowledging its limitations:
- Small sample sizes: The largest individual fibromyalgia RCT (Due Bruun 2024) included 99 participants. Most earlier trials had fewer than 40. This limits the statistical power to detect moderate treatment effects.
- Short trial durations: Most trials ran for 8 to 16 weeks. Fibromyalgia and ME/CFS are lifelong conditions. Long-term efficacy and safety data beyond 1 to 2 years is limited to retrospective clinical observations.
- Heterogeneous study designs: Different trials used different doses (3mg, 4.5mg, 6mg), different outcome measures, and different patient populations. This makes meta-analysis interpretation more complex.
- No large-scale phase III trial completed: The INNOVA trial (a 120-patient phase III RCT of LDN 4.5mg for fibromyalgia, 12 months duration) is currently underway in Spain. This is the type of trial that could substantially shift the evidence landscape.
- Pharmaceutical economics: Naltrexone is a generic, inexpensive drug that cannot be patented in a new indication. This reduces commercial incentive for pharmaceutical companies to fund the large trials that regulatory approval would require. The result is that most LDN research is funded by academic institutions and patient advocacy organizations.
These limitations do not mean LDN is ineffective. They mean that definitive evidence has not yet arrived. For patients who have exhausted approved options and are seeking a low-risk alternative with a plausible biological rationale, the existing evidence may be sufficient to justify a clinical conversation with their GP.
The Bottom Line on LDN for Fibromyalgia and Chronic Fatigue in Australia
Fibromyalgia and ME/CFS are conditions that demand a patient-centred, evidence-informed approach. No single treatment works for everyone.
LDN sits in a growing category of emerging therapies with a plausible biological mechanism, a favourable safety profile, and an encouraging body of clinical evidence that is still being built. It is not a cure. It does not work for everyone. The published response rates suggest that roughly 30 to 60 percent of patients experience clinically meaningful improvement, depending on the study and condition.
For patients who have tried standard treatments without adequate relief, LDN offers a different mechanism and a different conversation worth having with a GP who understands the evidence and takes an integrative approach to chronic conditions.
Australian clinical trials at Griffith University and international trials at Harvard, UBC, and in Spain are actively generating the larger-scale data that will clarify LDN’s role. In the meantime, off-label prescribing by informed, AHPRA-registered GPs continues to offer access to this therapy for patients who are appropriate candidates.
Book Your Integrative Health Consultation
Holistica Health provides integrative GP consultations for patients nationwide in Australia. No referral required.
Initial integrative health consultation: $99. Available Australia-wide via telehealth.
Complete our pre-screening eligibility check to get started: holisticahealth.com.au/Bookyourconsult/pre-screening-checklist/
Frequently Asked Questions
Is low dose naltrexone TGA approved in Australia?
No. Naltrexone is TGA approved in Australia at the standard 50mg dose for alcohol and opioid dependence only. LDN at doses of 1.5 to 4.5mg is prescribed off-label for conditions including fibromyalgia and ME/CFS. Off-label prescribing is a standard and legal part of Australian medical practice when supported by clinical evidence and informed patient consent. LDN is dispensed by a compounding pharmacy because no commercial product exists at the required low doses.
Can I take LDN if I am currently on opioid pain medications?
No. LDN is a low-dose opioid antagonist, meaning it blocks opioid receptors. Taking LDN alongside opioid medications would reduce or eliminate their effect and could trigger withdrawal symptoms. A washout period is required before starting LDN if you have been taking opioids. Always disclose all current medications to your GP.
How long does LDN take to work?
Patients who respond to LDN typically notice changes over 4 to 12 weeks. The medication is usually started at 1.5mg daily and titrated up to the target dose over several weeks. Some patients require 3 to 6 months before experiencing meaningful improvement. A clinical review at 3 to 6 months is standard practice to assess whether the treatment is providing benefit.
Do I need a specialist referral to access LDN in Australia?
No. Any AHPRA-registered GP can prescribe LDN off-label if they determine it is clinically appropriate for your situation. At Holistica Health, integrative health consultations are available via telehealth across all Australian states and territories. The initial consultation is $99. You can start by completing the pre-screening eligibility check on the Holistica Health website.
Is LDN the same medication used for addiction treatment?
Yes, it is the same drug (naltrexone) but at a much lower dose. Standard naltrexone for alcohol or opioid dependence is prescribed at 50mg daily. LDN for chronic pain and fatigue is prescribed at 1.5 to 4.5mg daily. At this low dose, it appears to act through a different mechanism, reducing neuroinflammation through microglial modulation and TLR4 antagonism, rather than primarily blocking opioid receptors.